Business & EconomyHealth
Moderna Stock Nearly Triples on Cancer Vaccine Trial
Moderna shares surged 177% after its personalized mRNA cancer vaccine met Phase 3 endpoints in melanoma, marking a historic milestone for cancer treatment.
—6 min read
Tag
#Moderna
9 articles
HealthBusiness
Moderna Surges After mRNA Cancer Treatment Passes Trial
Moderna and Merck announce their mRNA-based cancer vaccine intismeran met key endpoints in a Phase 3 melanoma trial, sending Moderna shares up over 120%.
—6 min read
Health
FDA Approves Moderna's mRNA Flu Vaccine, a First
The FDA has approved Moderna's mFLUSIVA, the first mRNA-based flu vaccine, for adults 50 and older. The approval marks a milestone in vaccine technology.
—5 min read
HealthPolitics
FDA to Decide on mRNA Flu Shot That RFK Jr. Questioned
The FDA faces an Aug. 5 decision on Moderna's mRNA flu shot — a first for the U.S. and a test of vaccine policy under HHS Secretary RFK Jr.'s skepticism.
—5 min read
HealthScience
FDA Panel Unanimously Backs First New Vaccine Since 2023
An FDA advisory committee voted 9-0 to recommend Moderna's mRNA flu vaccine, marking the panel's first new vaccine endorsement in over three years.
—5 min read
ScienceHealth
mRNA Flu Vaccine Offers Broader, Longer-Lasting Immunity
Moderna's mRNA-1010 flu vaccine triggers broader antibody responses and durable immunity against multiple influenza strains, study finds.
—4 min read
HealthMedical Research
mRNA Cancer Vaccine Slashes Melanoma Recurrence by 49%
Moderna and Merck's mRNA vaccine reduced melanoma recurrence risk by 49% over five years, offering new hope for advanced skin cancer patients.
—4 min read
Health & ScienceTechnology
mRNA Vaccine Cuts Melanoma Recurrence Risk by 49% in Trial
A personalized mRNA cancer vaccine from Moderna and Merck reduced melanoma recurrence risk by 49% over five years, marking a major advance.
—4 min read
HealthMedical Research
mRNA Vaccine Shows Lasting Protection Against Melanoma
A personalized mRNA cancer vaccine combined with Keytruda reduced melanoma recurrence risk by 49% over five years, according to new clinical trial data.
—4 min read